Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion.
Mesangial expansion, the principal glomerular lesion in diabetic nephropathy, is preceded by a phenotypic activation and transient proliferation of the glomerular mesangial cells and by a prominent glomerular infiltration of monocytes and macrophages. Because this infiltration seems to play a key role in the subsequent mesangial matrix expansion, we tested the response of cultures of rat mesangial cells (RMCs) for monocyte adhesion in response to hyperglycemia. Increasing the medium glucose concentration from 5.6 mm (normal) to 25.6 mm (hyperglycemic) significantly increased hyaluronan in the cell matrix, with a concurrent 3- to 4-fold increase in adhesion of U937 monocytic leukemic cells to cultures of near confluent RMCs. These responses were attributed directly to the high glucose concentration and not to increased extracellular osmolality. The monocytes primarily bind directly to hyaluronan-based structures in vitro. Abnormal deposits of hyaluronan were found in glomeruli of kidney sections from diabetic rats 1 week after streptozotocin treatment, often with closely associated monocytes/macrophages, suggesting that similar structures are relevant in vivo. The monocyte adhesion response to high glucose concentration required growth stimulation of RMCs by serum and activation of protein kinase C, and was inhibited by prior passage of the RMCs in the presence of heparin. These results suggest that the response may be cell growth state and protein kinase C-dependent. When incubated with the viral mimetic, poly I:C, in the presence of normal glucose, heparin-passaged RMCs still increased cell-associated hyaluronan and exhibited hyaluronan-mediated adhesion of monocytes, indicating that the two stimuli, high glucose and viral mimetic, induce the production of the hyaluronan structures that promote monocyte adhesion by distinctly different intracellular signaling mechanisms.
Wang
Aimin
A
Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. wanga@bme.ri.ccf.org
Hascall
Vincent C
VC
D000818:Animals; D002448:Cell Adhesion; D002455:Cell Division; D002478:Cells, Cultured; D002810:Chondroitinases and Chondroitin Lyases / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D019286:Endopeptidase K / Q000378:metabolism; D005920:Glomerular Mesangium / Q000166:cytology*; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry* / Q000494:pharmacology; D006821:Hyaluronoglucosaminidase / Q000378:metabolism; D006943:Hyperglycemia; D007678:Kidney Glomerulus / Q000378:metabolism; D018613:Microscopy, Confocal; D009000:Monocytes / Q000166:cytology* / Q000378:metabolism; D010641:Phenotype; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D015398:Signal Transduction; D013311:Streptozocin / Q000494:pharmacology; D013997:Time Factors; D020298:U937 Cells
D013311:Streptozocin; D006820:Hyaluronic Acid; D006493:Heparin; D011493:Protein Kinase C; D006821:Hyaluronoglucosaminidase; D019286:Endopeptidase K; D002810:Chondroitinases and Chondroitin Lyases; D005947:Glucose